European CHMP recommends approval of caffeine citrate (Gencebok) for treatment of primary apnoea of premature newborns

Gencebok will be available as 10 mg/ml solution for infusion. Gencebok is a hybrid medicine of Peyona (authorised in the EU since 2009); it contains the same active substance as Peyona 20mg/ml, but it is available in a different strength.


European Medicines Agency